Proteolysis in human breast and colorectal cancer (original) (raw)

Abstract

Proteolysis occurs when proteinase activity exceeds inhibitor activity. Proteolysis is normally tightly regulated and is involved in cancer invasion and metastasis. The aim of this study was to compare proteolysis in breast and colorectal cancer. Proteinase and inhibitor expression were analysed in paired tumour and normal tissue samples from 43 breast and 24 colorectal cancer patients using substrate zymography, Western blotting and quenched fluorescence substrate hydrolysis. The expression of the latent forms of matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-9, urokinase plasminogen activator (uPA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression were observed in both tumour and normal tissue samples from breast and colorectal tissue; however, expression was greater in the tumour tissue. Expression of active MMP-2 and MMP-9 and the total MMP activity were greater in tumour compared to normal samples in both tissues (P< 0.05). The expression of all proteinases and total MMP activity was greater in colorectal tissue than breast tissue samples. Breast and colorectal cancer demonstrated different proteinase profiles, however proteolysis in both tissues was greater in tumour tissue than normal tissue. © 1999 Cancer Research Campaign

Keywords: proteolysis, matrix metalloproteinases (MMPs), breast cancer, colorectal cancer, metastasis

Full Text

The Full Text of this article is available as a PDF (91.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baramova E., Foidart J. M. Matrix metalloproteinase family. Cell Biol Int. 1995 Mar;19(3):239–242. [PubMed] [Google Scholar]
  2. Barrett A. J. Classification of peptidases. Methods Enzymol. 1994;244:1–15. doi: 10.1016/0076-6879(94)44003-4. [DOI] [PubMed] [Google Scholar]
  3. Bouchet C., Spyratos F., Martin P. M., Hacène K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994 Feb;69(2):398–405. doi: 10.1038/bjc.1994.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown C. J., Rahman S., Morton A. C., Beauchamp C. L., Bramwell H., Buttle D. J. Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity. Clin Mol Pathol. 1996 Dec;49(6):M331–M339. doi: 10.1136/mp.49.6.m331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown P. D., Bloxidge R. E., Anderson E., Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis. 1993 Mar;11(2):183–189. doi: 10.1007/BF00114976. [DOI] [PubMed] [Google Scholar]
  6. Buø L., Meling G. I., Karlsrud T. S., Johansen H. T., Aasen A. O. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol. 1995 Oct;26(10):1133–1138. doi: 10.1016/0046-8177(95)90276-7. [DOI] [PubMed] [Google Scholar]
  7. Cawston T. E., Murphy G., Mercer E., Galloway W. A., Hazleman B. L., Reynolds J. J. The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J. 1983 May 1;211(2):313–318. doi: 10.1042/bj2110313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clavel C., Polette M., Doco M., Binninger I., Birembaut P. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bull Cancer. 1992;79(3):261–270. [PubMed] [Google Scholar]
  9. Conway J. G., Trexler S. J., Wakefield J. A., Marron B. E., Emerson D. L., Bickett D. M., Deaton D. N., Garrison D., Elder M., McElroy A. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis. 1996 Mar;14(2):115–124. doi: 10.1007/BF00121208. [DOI] [PubMed] [Google Scholar]
  10. Corcoran M. L., Hewitt R. E., Kleiner D. E., Jr, Stetler-Stevenson W. G. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996;49(1-3):7–19. doi: 10.1159/000468613. [DOI] [PubMed] [Google Scholar]
  11. Davies B., Miles D. W., Happerfield L. C., Naylor M. S., Bobrow L. G., Rubens R. D., Balkwill F. R. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 1993 May;67(5):1126–1131. doi: 10.1038/bjc.1993.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Duffy M. J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J. J. Urokinase plasminogen activator and prognosis in breast cancer. Lancet. 1990 Jan 13;335(8681):108–108. doi: 10.1016/0140-6736(90)90571-l. [DOI] [PubMed] [Google Scholar]
  13. Gallegos N. C., Smales C., Savage F. J., Hembry R. M., Boulos P. B. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol. 1995;4(2):111–119. doi: 10.1016/s0960-7404(10)80015-5. [DOI] [PubMed] [Google Scholar]
  14. Grøndahl-Hansen J., Ralfkiaer E., Kirkeby L. T., Kristensen P., Lund L. R., Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol. 1991 Jan;138(1):111–117. [PMC free article] [PubMed] [Google Scholar]
  15. Hamdy F. C., Fadlon E. J., Cottam D., Lawry J., Thurrell W., Silcocks P. B., Anderson J. B., Williams J. L., Rees R. C. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer. 1994 Jan;69(1):177–182. doi: 10.1038/bjc.1994.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Heppner K. J., Matrisian L. M., Jensen R. A., Rodgers W. H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996 Jul;149(1):273–282. [PMC free article] [PubMed] [Google Scholar]
  17. Heussen C., Dowdle E. B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 1980 Feb;102(1):196–202. doi: 10.1016/0003-2697(80)90338-3. [DOI] [PubMed] [Google Scholar]
  18. Hewitt R. E., Leach I. H., Powe D. G., Clark I. M., Cawston T. E., Turner D. R. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer. 1991 Nov 11;49(5):666–672. doi: 10.1002/ijc.2910490507. [DOI] [PubMed] [Google Scholar]
  19. Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991 Jul;17(3):303–312. doi: 10.1055/s-2007-1002624. [DOI] [PubMed] [Google Scholar]
  20. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
  21. Khokha R., Martin D. C., Fata J. E. Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Cancer Metastasis Rev. 1995 Jun;14(2):97–111. doi: 10.1007/BF00665794. [DOI] [PubMed] [Google Scholar]
  22. Knight C. G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263–266. doi: 10.1016/0014-5793(92)80300-6. [DOI] [PubMed] [Google Scholar]
  23. Kwaan H. C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992 Nov;11(3-4):291–311. doi: 10.1007/BF01307184. [DOI] [PubMed] [Google Scholar]
  24. Liabakk N. B., Talbot I., Smith R. A., Wilkinson K., Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996 Jan 1;56(1):190–196. [PubMed] [Google Scholar]
  25. Matrisian L. M., Wright J., Newell K., Witty J. P. Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp. 1994;24:152–161. [PubMed] [Google Scholar]
  26. Murray G. I., Duncan M. E., O'Neil P., Melvin W. T., Fothergill J. E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996 Apr;2(4):461–462. doi: 10.1038/nm0496–461. [DOI] [PubMed] [Google Scholar]
  27. Parsons S. L., Watson S. A., Collins H. M., Griffin N. R., Clarke P. A., Steele R. J. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer. 1998 Dec;78(11):1495–1502. doi: 10.1038/bjc.1998.712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Polette M., Clavel C., Cockett M., Girod de Bentzmann S., Murphy G., Birembaut P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis. 1993;13(1):31–37. [PubMed] [Google Scholar]
  29. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991 May;138(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  30. Remacle A. G., Noël A., Duggan C., McDermott E., O'Higgins N., Foidart J. M., Duffy M. J. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer. 1998 Mar;77(6):926–931. doi: 10.1038/bjc.1998.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schmitt M., Goretzki L., Jänicke F., Calvete J., Eulitz M., Kobayashi H., Chucholowski N., Graeff H. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta. 1991;50(4-6):731–741. [PubMed] [Google Scholar]
  32. Seftor R. E. Electrophoretic analysis of proteins associated with tumor cell invasion. Electrophoresis. 1994 Mar-Apr;15(3-4):454–462. doi: 10.1002/elps.1150150162. [DOI] [PubMed] [Google Scholar]
  33. Stonelake P. S., Jones C. E., Neoptolemos J. P., Baker P. R. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer. 1997;75(7):951–959. doi: 10.1038/bjc.1997.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., Brown P. D., Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 1995 Feb 15;87(4):293–298. doi: 10.1093/jnci/87.4.293. [DOI] [PubMed] [Google Scholar]
  35. Testa J. E., Quigley J. P. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev. 1990 Dec;9(4):353–367. doi: 10.1007/BF00049524. [DOI] [PubMed] [Google Scholar]
  36. Torii A., Kodera Y., Uesaka K., Hirai T., Yasui K., Morimoto T., Yamamura Y., Kato T., Hayakawa T., Fujimoto N. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg. 1997 Jan;84(1):133–136. [PubMed] [Google Scholar]
  37. Yu A. E., Hewitt R. E., Connor E. W., Stetler-Stevenson W. G. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging. 1997 Sep;11(3):229–244. doi: 10.2165/00002512-199711030-00006. [DOI] [PubMed] [Google Scholar]